Scientists Study HIV Drug Resistance Tests
Posted on: Tuesday, 27 September 2005, 18:00 CDT
Boston scientists say drug-resistance testing in HIV-infected patients at the time of diagnosis is cost-effective and may increase life expectancy.
A cost-effectiveness analysis indicates performing genotype resistance testing at initial HIV diagnosis -- prior to treatment -- can effectively guide a physician's choice of treatment regimen and increase a patient's quality-adjusted life expectancy.
For the approximately 90 percent of patients with no resistance, the testing provides no benefit, said lead author Dr. Paul Sax of Brigham and Women's Hospital. However, if certain types of resistance are present, our study projects a substantial increase in survival of more than 14 months, compared with no resistance testing.
It's estimated that in the United States and Europe, the average resistance rate in treatment-naive patients is between 8 percent and 10 percent, although baseline resistance may be as high as 16 percent in gay men.
Using a model with a resistance rate of just more than 8 percent, the analysis estimated a cost of $23,900 per quality-adjusted life year gained.
The research appears in the Nov. 1 online issue of Clinical Infectious Diseases.
Source: United Press International
Related Articles
- For Treatment of Dyslipidemia, Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials
- Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients
- Small Businesses Cite Energy As "Biggest Cost Increase" Over the Past Two Years
- Pharmacy Benefit Management Institute Research Confirms Employers' Drug Cost Increases Remain in Single Digits
- The Molecular Profiling Institute Launches Mammostrat(TM) - A Novel, Molecular-Targeted, Prognostic Test for Breast Cancer Patients
- Clinical Data and George Washington University Establish Relationship to Examine Impact of Genetic Testing in Warfarin Treatment
- Chronic Conditions to Cause Greatest Health Care Costs Increases
- Little Relief From Health Benefit Cost Increases Expected, Watson Wyatt, National Business Group On Health Survey Finds
- Firm Tests New Cancer Treatment With Reduced Side-Effects
- U.S. Companies Face Lowest Health Care Cost Increases Since 1999, According to Hewitt Associates
 |
 |
User Comments (0)
RSS Feeds